JIGAR K SHAH, M.D

I. WORK EXPERIENCE:

A. Arthritis and Rheumatology Center of South Florida 3/2018-

- *Founder:* Margate, FL 33063
- *Staff Privileges:* Broward Health North, Broward Coral Springs, Broward Imperial Point, Northwest Medical Center, West Boca Medical Center

B. Northwest Medical Center Residency Program 2019-

- *Rheumatologist:* Clinical Assistant Professor

C. Arthritis and Rheumatic Disease Specialties Medical Center 11/2015- 2/2018

- *Rheumatologist:* Aventura, FL

D. Nexus Medical Consulting 5/2017-1/2018

E. Coral Springs Medical Center/Imperial Point Medical Center 11/2012-11/2017

- *Hospitalist* with Sound Physicians and Schumacher Physicians Coral Springs and Fort Lauderdale, FL

II. LICENSURE AND CERTIFICATIONS:

A. Board Certified in Rheumatology and Internal Medicine

B. Active Florida License and DEA

III. NATURALIZATION STATUS:

United States Citizen

- Born in Palm Beach Gardens, FL on November 11, 1983

IV. EDUCATION:

A. SUNY Downstate University Medical Center in Brooklyn, NY 7/2013-7/2015

- Rheumatology Fellow
- Responsibilities include:
  - Active coverage of inpatient rheumatology consultations
  - Performing procedures such as joint aspiration and musculoskeletal Injections
  - Evaluating and enrolling patients into clinical trials of new therapeutic agents, especially for SLE
  - Placing infusion orders for biologic agents in the outpatient chemotherapy unit and for clinical trial patients

- Training in Musculoskeletal Ultrasound at the VA campus with US Sonosite

B. SUNY Downstate University of Brooklyn at Long Island College Hospital 6/2009-6/2012
- Internal Medicine

C. St. George's University School of Medicine, St. George's, Grenada 8/2005-6/2009

D. University of Miami, Coral Gables, Florida 8/2001- 5/2005
- Bachelor of Science - Majors in Biology and Psychology with Minor in Chemistry

V. PHARMACEUTICAL

A. Aurinia Pharmaceuticals Advisory Board 12/2020
B. GlaskoSmithKline Pharmaceutical Speaker: Benlysta 6/2019-
C. OraPharma Pharmaceutical Speaker: NeutraSal 7/2018-
D. Abbvie Pharmaceutical Speaker: Humira 8/2017-
E. Horizon Pharmaceutical Speaker: Krystexxa 3/2017-
F. Celegene Advisory Board: Otezla 6/2017
G. Jannsen Advisory Board: Simponia Aria 12/2016/19

VI. RESEARCH EXPERIENCE/ABSTRACTS:

A. Life Clinical Trials 2019-
- Principal Investigator

Eli Lilly: "A Randomized,Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)," protocol I4V-MC-JAHZ ("Protocol")

Eli Lilly: Baricitinib (LY3009104) A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis

VielaBio: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients with Rheumatoid Arthritis (RA) (short title: MIDORA)

Emerald: A Phase IIa, Double-Blind, Randomized, Intracohort Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101 in Patients with Diffuse Cutaneous Systemic Sclerosis

Idorsia: A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in

subjects with moderate to severe systemic lupus erythematosus (SLE)

GSK A 52-week, phase 3, multicenter, randomized, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in participants with moderately to severely active
rheumatoid arthritis who have an inadequate response to conventional synthetic DMARDs or biologic DMARDs.

GSK A 24-week, phase 3, multicenter, randomized, double-blind, efficacy and safety study, comparing GSK3196165 with placebo and with sarilumab, in combination with conventional synthetic DMARDs, in participants with moderately to severely active rheumatoid arthritis who have an inadequate response to biological DMARDs and/or Janus Kinase inhibitors.

GSK A multi-center long-term extension study to assess the safety and efficacy of GSK3196165 in the treatment of rheumatoid arthritis.

HZNP-KRY-405
Horizon A Phase 1b, Combined Single-Dose and Multiple-Dose, Multicenter, Randomized, Open-Label Trial to Assess Safety and Tolerability of Two Different Dose Levels of Subcutaneous Pegloticase in Subjects with Uncontrolled Gout Receiving Methotrexate

HZNP-KRY-407
Horizon A Phase 4, Multicenter, Open-label, Efficacy and Safety Trial of Pegloticase and Methotrexate Co-administered in Patients with Uncontrolled Gout who have Previously Received Pegloticase Monotherapy but did not Maintain a Serum Uric Acid Response

Novartis Pharmaceuticals trial entitled: A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis

B. AARDS Research, Inc. 2015-2018
- Sub-Investigator at 21097 NE 27th Court, Suite 200, Aventura, FL 33180
- Performing physical examinations, joint assessments, PsA assessments, and disease activity assessments associated with rheumatic diseases

B. Descriptive Review of Knee Osteoarthritis in Systemic Lupus Erythematous Patients 2015
- Co-principal Investigator

C. Sub investigator: Department of Rheumatology, SUNY Downstate Medical Center 2013-2015

GSK/HGS: A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE) (Protocol # HGS 1006-C1112/ GSK BEL 115471)

GSK/HGS A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo Plus Standard of Care in Adult Subjects with Active Lupus Nephritis (Protocol # HGS 1006- C1121/GSK BEL 114054)

GSK/HGS: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Systemic Lupus Erythematosus (SLE)) Protocol # HGS 1006-C1115/ GSK BEL 112341)

GSK/HGS: A Multi-Center, Open-Label Continuation Trial of LyphoStat-B Antibody (Monoclonal Anti-BlyS Antibody) in Subjects with Systemic Lupus Erythematosus (SLE) Who Completed the Phase 2 Protocol LBSL02 (Protocol# LBSL99)

GSK/HGS: A Multi-Center Continuation Trial of Belimumab (HGS 1006, LymphoStat-B) a Fully Human Monoclonal Anti-BlyS Antibody in Subjects with Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS 1006-C1056 in the United States (Human Genome Sciences, Inc. HGS1006-C1066)

BMS: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil (MMF) and Corticosteroids in Subjects with Active Class III or IV Lupus Nephritis (Protocol # IM101-291)

Takeda Development Center Americas Inc.: A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of MLN9708 for the Treatment of Subjects with ISN / RPS Class III or IV Lupus Nephritis. Protocol Number: MLN9708_101

Aurinia Pharmaceuticals Inc.: Phase II A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) with Placebo in Achieving Remission in Patients with Active Lupus Nephritis. Protocol #AUR-VCS-2012-01

Lupus Clinical Trials Consortium, Inc.: A Prospective Registry to Study Presentation, Clinical Course, Treatment Patterns, and Outcomes in Patients with Systemic Lupus Erythematosus

D. American Thoracic Society Abstract: **Extra-Meningeal Manifestations Of Fulminant Meningococcemia: An Intensivist Perspective** 2012

E. American Thoracic Society Abstract: **Propylene Glycol Intoxication Without An Anion Gap Metabolic Acidosis** 2012

F. **Comparative effectiveness and time to response among adalimumab, abatacept, etanercept, and infliximab for the treatment of rheumatoid arthritis in a real world routine case registry.** 2010-2011

Research Assistant – working directly with Dr. Yusuf Yazici (NYU-Joint Disease)

G. ACP NY Abstract **: Invasive Mucinous Carcinoma in a Male Breast** 2011

H. University of Miami – Behavioral Medicine Research Center 2003-2005

- *Research Assistant* - Positive Survivors Research Study – examined how stress affects the health and immunity of people living with HIV.

VII. EXTRACURRICULAR ACTIVITIES/LEADERSHIP ROLES:

A. Broward County Medical Association Member 2018-

B. Florida Society of Rheumatology Member 2017-

C. American College of Rheumatology Member 2012-

D. Indian Physicians of South Florida Member 2018-

E. Biology Workshop Leader 2004-2005

- Mentored students in addition to teaching them Biology.

F. Canes Chess Club Co-founder and President 2003-2004

- Organized chess club meetings and interactive tournaments

G. United States Presidential Debate Volunteer Committee 2004

- Assisted in coordinating various events leading up to the Presidential Debate and during the Debate at the University of Miami.

VIII. QUALITY IMPROVEMENT PROJECTS:

A. Influenza Vaccine Rate in Rheumatology Patients 2015

B. Hospital Readmission Rates within the past 30 days 2012

IX. AWARDS/PRESENTATIONS/CONFERENCES:

A. Arthritis Foundation of South Florida: Rheumatologist of the Year 2019

B. American College of Rheumatology Knowledge Bowl Participant 2014

C. Scholarship for International Society of Clinical Densitometry 4th Osteoporosis Academy 2012

X. PERSONAL INTERESTS AND HOBBIES:

A. Golf

B. Traveling

REFERENCES UPON RQUEST